Geron (GERN) Stock Price, News & Analysis

Company Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $3.45 to $3.68
• 50-Day Range: $3.49 to $4.29
• 52-Week Range: $1.64 to $5.34
• Volume: 26.32 million shs
• Average Volume: 10.21 million shs
• Market Capitalization: $2.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.15
• Consensus Rating: Buy

Geron Stock Analysis - MarketRank™

Geron scored higher than 77% of companies evaluated by MarketBeat, and ranked 238th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Geron has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Geron has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Geron is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Geron is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Geron has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.98% of the outstanding shares of Geron have been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Geron has recently decreased by 5.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Geron does not currently pay a dividend.

Dividend Growth

Geron does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 1.3 / 5
• Environmental Score: -2.76

Percentage of Shares Shorted

10.98% of the outstanding shares of Geron have been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Geron has recently decreased by 5.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.91

News Sentiment

Geron has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Geron this week, compared to 6 articles on an average week.

Search Interest

11 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Geron insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Geron is held by insiders.

Percentage Held by Institutions

73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GERN Stock Analysis - Frequently Asked Questions

How have GERN shares performed this year?

Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN shares have increased by 65.4% and is now trading at $3.49.
View the best growth stocks for 2024 here.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The company's quarterly revenue was up 17138.4% compared to the same quarter last year.

Who are Geron's major shareholders?

Top institutional investors of Geron include RTW Investments LP (7.30%), RA Capital Management L.P. (5.34%), State Street Corp (4.79%) and Janus Henderson Group PLC (3.73%). Insiders that own company stock include John A Scarlett, Olivia Kyusuk Bloom, Elizabeth G O'farrell, Faye Feller and Andrew J Grethlein.
View institutional ownership trends.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol-Myers Squibb (BMY).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GERN
• CUSIP: 37416310
• CIK: 886744
• Web: www.geron.com
• Phone: (650) 473-7700
• Fax: 650-473-7750
• Employees: 141
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.15
• High Stock Price Target: $10.00
• Low Stock Price Target: $4.50
• Potential Upside/Downside: +104.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-184,130,000.00
• Net Margins: -682.48%
• Pretax Margin: -682.47%
• Return on Equity: -67.53%
• Return on Assets: -45.46%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 2.89
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $29.48 million
• Price / Sales: 71.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 7.59

Miscellaneous

• Outstanding Shares: 604,501,000
• Free Float: 585,761,000
• Market Cap: $2.11 billion
• Optionable: Optionable
• Beta: 0.51